GAO: Medicare’s Opioid Use Monitoring Lets At-Risk Patients Fall Through the Cracks

Drug Industry Daily
The federal government’s guidance for monitoring opioid use among Medicare beneficiaries does not go far enough in identifying which beneficiaries are most at risk and the Centers for Medicare & Medicaid Services should collect data on exactly how many at-risk beneficiaries receive high doses, according to a new GAO report.

To View This Article:


Subscribe To Drug Industry Daily